All In Biotech

Drug Trial Radar · NCT03563170

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy w/ Adenoviral & Yeast-based Vaccines to Induce T-cell Responses in Subjects w/ Advanced, Unresectable & Untransplantable HCC

Last checked: Nov 20, 2026Latest source record: Mar 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

May 25, 2018

Primary completion

Aug 23, 2019

Study completion Aug 23, 2019

Sponsor

Lead sponsor
ImmunityBio, Inc.Industry
Sponsor type
Industry
First posted
Jun 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with advanced, unresectable, and untransplantable HCC.

Conditions

  • Hepatocellular Carcinoma Non-resectable
  • Hepatocellular Carcinoma Recurrent

Interventions

  • ETBX-011Biological

    Ad5 \[E1-, E2b-\]-CEA

  • GI-4000Biological

    Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins

  • haNK for infusionBiological

    NK-92 \[CD16.158V, ER IL-2\]

  • avelumabBiological

    Recombinant human anti-PD-L1 IgG1 monoclonal antibody

  • CapecitabineDrug

    5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

  • CyclophosphamideDrug

    anhydrous

  • 5-FluorouracilDrug

    5-FU; Fluorouracil

  • LeucovorinDrug

    Leucovorin calcium salt

  • nab-PaclitaxelDrug

    ABRAXANE® \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]

  • SorafenibDrug

    NEXAVAR® tablets, for oral use

  • SBRTProcedure

    Stereotactic Body Radiation Therapy

  • Aldoxorubicin hydrochlorideBiological

    HCl

  • ETBX-051Biological

    Ad5 \[E1-, E2b-\]-Brachyury vaccine

  • ETBX-061Biological

    Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine

  • GI-6207Biological

    CEA yeast vaccine

  • GI-6301Biological

    Brachyury yeast vaccine

  • CetuximabDrug

    ERBITUX® injection, for IV infusion)

  • N-803Biological

    Recombinant human super agonist IL-15 complex \[also known as IL-15N72D:IL- 15RαSu/IgG1 Fc complex\]

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03Time frame: 2 years
  2. Evaluate the overall safety profile in subjects with advanced, unresectable, untransplantable HCC who have progressed or experienced unacceptable toxicity on prior sorafenib treatment. Measured / reported based on the tumor size imaging per RECIST 1.1.Time frame: 2 years
  3. Progression Free Survival from baseline to progression, per RECIST 1.1Time frame: 2 years
  4. Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chan Soon-Shiong Institute for Medicine

    El Segundo, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.